Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Guang Tan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3591-8685; OpenAlex author ID A5018588746. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 10

  1. A novel mitochondrial-associated risk score reveals a potential link between pancreatic ductal adenocarcinoma and chemotherapy resistance as well as poor respo… First author DOI 10.1007/s12672-026-05006-z↗
  2. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  3. Correlation between Macrophage Polarization and PD-L1-Related Tumor Microenvironmental Alteration and Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2023/7971306↗
  4. Correlation between pancreatic cancer and metabolic syndrome: A systematic review and meta-analysis. Last author DOI 10.3389/fendo.2023.1116582↗
  5. Cancer associated fibroblasts (CAFs) derived exosomes with A promoted liver metastasis of pancreatic cancer by regulating C through transcription factor B Co-author DOI 10.21203/rs.3.rs-1464033/v1↗
  6. Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go? First author DOI 10.3389/fonc.2022.828223↗
  7. Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer. Co-author DOI 10.1155/2020/1570862↗
  8. Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with 99mTc-Hynic-PEG-AE105. Last author DOI 10.3892/ol.2015.3504↗
  9. Aberrant elevated microRNA-146a in dendritic cells (DC) induced by human pancreatic cancer cell line BxPC-3-conditioned medium inhibits DC maturation and activ… Co-author DOI 10.1007/s12032-012-0175-2↗
  10. The therapeutic effect of cytokine-induced killer cells on pancreatic cancer enhanced by dendritic cells pulsed with K-ras mutant peptide. Co-author DOI 10.1155/2011/649359↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qi Zhang · 1 shared paper, 2026 · strength 0.63
  2. Haifeng Luo · 5 shared papers, 2011–2023 · strength 0.61
  3. Jiangning Gu · 3 shared papers, 2020–2023 · strength 0.39
  4. Jian Du · 3 shared papers, 2012–2022 · strength 0.32
  5. Dan Chen · 2 shared papers, 2022–2023 · strength 0.29
  6. Chenqi Wang · 2 shared papers, 2022–2023 · strength 0.29
  7. Jifeng Liu · 1 shared paper, 2023 · strength 0.26
  8. Lei Zhong · 1 shared paper, 2023 · strength 0.26
  9. Wei Li · 1 shared paper, 2026 · strength 0.23
  10. Chunyi Hao · 1 shared paper, 2026 · strength 0.23
  11. Haitao Zhang · 1 shared paper, 2026 · strength 0.23
  12. Ke Cheng · 1 shared paper, 2026 · strength 0.23
  13. Liwei Wang · 1 shared paper, 2026 · strength 0.23
  14. Huanji Xu · 1 shared paper, 2026 · strength 0.23
  15. Dan Cao · 1 shared paper, 2026 · strength 0.23
  16. Jianhui Wu · 1 shared paper, 2026 · strength 0.23
  17. Jiujie Cui · 1 shared paper, 2026 · strength 0.23
  18. Kuirong Jiang · 1 shared paper, 2026 · strength 0.23
  19. Qi Li · 1 shared paper, 2026 · strength 0.23
  20. Guanghai Dai · 1 shared paper, 2026 · strength 0.23
  21. Shukui Qin · 1 shared paper, 2026 · strength 0.23
  22. Zhen Ning · 1 shared paper, 2022 · strength 0.19
  23. Lili Yang · 1 shared paper, 2022 · strength 0.13
  24. Yunlong Chen · 1 shared paper, 2022 · strength 0.13
  25. Xiang 'Anthony' Chen · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.